The Library
Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin : a ‘real-world’ view
Tools
Tools
Tools
McFarlane, Michael J., Chambers, Samantha, Malik, Ahmad, Lee, Bee, Sung, Edmond, Nwokolo, Chuka U., Waugh, Norman and Arasaradnam, Ramesh P. (2016) Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin : a ‘real-world’ view. BMJ Open, 6 (6). pp. 1-6. e011041. doi:10.1136/bmjopen-2016-011041
![[img]](http://wrap.warwick.ac.uk/style/images/fileicons/application_pdf.png) |
PDF
WRAP_BMJ Open-2016-McFarlane-.pdf - Unspecified Version - Requires a PDF viewer. Download (1143Kb) |
Official URL: http://dx.doi.org/10.1136/bmjopen-2016-011041
Abstract
Objectives:
A recent systematic review confirmed the usefulness of fecal calprotectin (FC) in distinguishing organic (inflammatory bowel disease (IBD)) from non-organic gastrointestinal disease (irritable bowel syndrome (IBS)). FC levels <50 μg/g have a negative predictive value >92% to exclude organic gastrointestinal (GI) disease. Levels >250 μg/g correlate with endoscopic IBD disease activity; sensitivity 90%. We aimed to determine clinical outcomes in intermediate raised FC results (50–250 μg/g).
Setting:
Primary care general practices in Coventry and Warwickshire, and 3 secondary care hospitals.
Participants:
443 FC results in adults (>16 years old) were reviewed from July 2012 to October 2013. Clinical data was collected from hospital databases and general practitioners. Long-term clinical data was available in 41 patients (out of 48).
Primary and secondary outcome measures:
The number of new diagnoses of IBD, IBS and other diagnoses for the intermediate group. The number referred and discharged from secondary care.
Results:
A new IBD diagnosis was made in 19% (n=8) of intermediate results (1% of normal and 38% of raised results). 5% (n=2) of intermediate results had known IBD in remission. A new IBS diagnosis was made in 27% (n=11) of intermediate results, while 34% (n=14) remained undiagnosed, although 8 of these were not referred to secondary care.
Conclusions:
FC testing remains useful in aiding diagnosis of organic GI conditions. However, unlike negative and strongly positive FC results, intermediate FC results lead to a mixture of diagnoses. The OR of a new diagnosis of IBD for an intermediate result compared to normal FC result was 26.6, while an intermediate FC result gave an OR of 0.54 for a new IBS diagnosis compared to normal FC. For intermediate FC results, 1 in 3 patients remained in secondary care after 12 months with an OR of 3.6 compared to a normal FC result.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine | ||||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
||||||||
| Library of Congress Subject Headings (LCSH): | Inflammatory bowel diseases | ||||||||
| Journal or Publication Title: | BMJ Open | ||||||||
| Publisher: | BMJ | ||||||||
| ISSN: | 2044-6055 | ||||||||
| Official Date: | 6 June 2016 | ||||||||
| Dates: |
|
||||||||
| Volume: | 6 | ||||||||
| Number: | 6 | ||||||||
| Number of Pages: | 6 | ||||||||
| Page Range: | pp. 1-6 | ||||||||
| Article Number: | e011041 | ||||||||
| DOI: | 10.1136/bmjopen-2016-011041 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Open Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
